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Aims: To investigate the association between long-term dipeptidyl peptidase-4 (DPP-4) inhibi-
tor use and risk of fracture among people with type 2 diabetes mellitus (T2DM).
Methods: A retrospective population-based cohort study, using data from the Clinical Practice
Research Datalink database (2007-2015), was conducted. All those (N = 328 254) with at least one
prescription for a non-insulin antidiabetic drug (NIAD), aged ≥18 years at the time of data collection,
were included. Cox proportional hazards models were used to estimate the hazard ratios of any frac-
ture, osteoporotic fracture and hip fracture in DPP-4 inhibitor users compared with those using other
NIADs. Analyses were stratified by continuous duration of DPP-4 inhibitor use. Time-dependent
adjustments were made for age, sex, lifestyle, comorbidity and concomitant drug use.
Results: Current use of DPP-4 inhibitors was not associated with risk of any fracture (adjusted
hazard ratio [HR] 0.99 [95% confidence interval {CI} 0.93-1.06]) as compared with current
other NIAD use. Current use of DPP-4 inhibitors was also not associated with risk of osteoporotic
or hip fracture. After stratification by continuous duration of DPP-4 inhibitor use the highest cate-
gory was not associated with any (>4.0-8.5 years of use, adjusted HR 0.99 [95% CI 0.70-1.41]),
osteoporotic (>3.0-8.5 years of use, adjusted HR 0.75 [95% CI 0.52-1.09]) or hip (>2.0-8.5 years of
use; adjusted HR 1.24 [95% CI 0.85-1.79]) fracture.
Conclusion: Continuous long-term DPP-4 inhibitor use (defined as >4.0-8.5 years of DPP-4
inhibitor use for any fracture, >3.0-8.5 years for osteoporotic fracture and >2.0-8.5 years for
hip fracture was not associated with risk of any, osteoporotic or hip fracture. These findings
may be of value for clinical decisions regarding treatment of patients with T2DM, especially
those at high risk of fracture.
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1 | INTRODUCTION
Worldwide, ~422 million people have type 2 diabetes mellitus
(T2DM).1 In addition to other complications, people with T2DM have
a greater risk of fracture compared with those without T2DM.2
Explanations for this elevated fracture risk include a higher risk of
falling,3 the effect of the pathophysiology of diabetes itself on bone qual-
ity4 as well as the effect of antihyperglycaemic drugs used in T2DM.5
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a relatively new
type of antihyperglycaemic drug which have been marketed since
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2006.6 It has been suggested that DPP-4 inhibitors might influence
bone metabolism and thereby potentially reduce fracture risk.5 A
first meta-analysis of randomized controlled trials (RCTs) indeed
showed a reduced risk of fracture with the use of DPP-4 inhibi-
tors.7 Recently, we performed the first observational studies inves-
tigating the association between use of DPP-4 inhibitors and risk
of fracture.8,9 In contrast to the results of the previous meta-analy-
sis, we found no association between use of DPP-4 inhibitors and
fracture risk. One of the explanations might be the fact that the
meta-analysis was based on a small number of fractures, which
were reported as severe adverse outcomes. By contrast, the obser-
vational studies used routinely collected data on fractures.
Recently, another observational study was published that compared
current use of metformin and DPP-4 inhibitors with non-use. Non-
use was defined as insufficient exposure to diabetes medication (ie,
a medication possession ratio <20%).10 This study showed no asso-
ciation with fracture risk when a DPP-4 inhibitor was added to
metformin.
A major limitation of both these observational studies as well as
the meta-analysis was the median actual duration of DPP-4 inhibitor
use. For the observational studies it ranged between 47 weeks9 and
1.04 years8 and for the meta-analysis the median duration of the
included trials was 24 weeks.7
Based on these findings, the limited duration of DPP-4 inhibitor
use might have been too short to show an association between use
of DPP-4 inhibitors and fracture risk; therefore, in the present study
we aimed to investigate the association between long-term use of
DPP-4 inhibitors and risk of fracture.
2 | MATERIALS AND METHODS
Data for the present study were obtained from the Clinical Practice
Research Datalink (CPRD) in the UK, previously known as the Gen-
eral Practice Research Database (http://www.CPRD.com). The CPRD
contains computerized medical records of 674 primary care practices
in the UK, representing 6.9% of the population.11 The data recorded
in the CPRD include demographic information, prescription details,
clinical events, preventive care provided, specialist referrals, hospital
admissions and major outcomes since 1987. Previous studies using
CPRD data have been shown to be highly valid, with, for example,
>90% confirmed diagnoses for hip fractures.12
We conducted a retrospective population-based cohort study.
The study population consisted of all patients with at least one pre-
scription for a non-insulin antidiabetic drug (NIAD), who were aged
≥18 years during the period of valid CPRD data collection. For this
study, data collection started on June 13, 2007, the date of the
first-ever prescription of a DPP-4 inhibitor in the CPRD, and ended
on December 31, 2015. The index date was defined as the date of
the first NIAD prescription since the start of the study period (ie,
the study population was a mix of incident and prevalent NIAD
users). Approval for this study was obtained from the independent
scientific advisory committee of the CPRD (protocol number:
12_161R).
2.1 | Exposure
The follow-up time for the NIAD users was divided into fixed inter-
vals of 30 days. When there was a prescription of a NIAD in the
90 days before the start of an interval, the interval was classified as
“current NIAD use,” otherwise the interval was classified as “past
NIAD use.” Patients were allowed to move between current and
past NIAD use. All DPP-4 inhibitor exposure intervals were classi-
fied, according to the time since the most recent prescription,
as current (1-90 days), recent (91-180 days) or past (over
180 days) use.
Continuous duration of use was determined at the start of every
interval. The prescribed quantity and the written dosage instruction
were used to estimate the duration of each DPP-4 inhibitor prescrip-
tion. Continuous duration was defined as the time from the first con-
tinuous prescription until the start of an interval, allowing a gap of
30 days13 between the estimated end date of a prescription and the
start of the next prescription.
2.2 | Outcome
Patients were followed up from the index date to either the end of
data collection, the date of transfer of the patient out of the practice
area, the patient’s death, or the fracture type of interest, whichever
came first. Fractures were classified by use of read codes.14 We used
the following categories to classify fractures: any, hip and osteopo-
rotic fracture. An osteoporotic fracture was defined as a fracture of
the hip, vertebrae, radius/ulna or humerus according to the World
Health Organisation (WHO) definition.15
2.3 | Potential confounders
The presence of risk factors was assessed by reviewing the compu-
terized medical records for any record of a risk factor prior to the
start of an interval. The following potential confounders were deter-
mined at baseline: sex; body mass index (BMI); smoking status; and
alcohol use. All other risk factors that were considered in this study
were determined time-dependently (ie, at the start of each interval).
We considered the following potential confounders: age; most recent
glycated haemoglobin (HbA1c) measurement in the year prior to the
start of an interval; occurrence of falls in the 7 to 12 months before
the start of an interval; a history of chronic obstructive pulmonary
disease; previous fracture; rheumatoid arthritis; hypothyroidism;
hyperthyroidism; cancer; retinopathy; neuropathy; congestive heart
failure; and secondary osteoporosis (hypogonadism or premature
menopause). In addition, the following drug prescriptions in the
6 months prior to the start of an interval were considered as poten-
tial confounders: oral glucocorticoids; cholesterol-modifying drugs;
antidepressants; anxiolytics or hypnotics; antipsychotics; anti-Parkin-
son’s drugs; antihypertensives (β blockers, thiazide diuretics, renin
angiotensin aldosterone system inhibitors, calcium channel blockers,
loop diuretics); antiarrhythmics; opposed hormone replacement ther-
apy; calcium; bisphosphonates; vitamin D; raloxifene; strontium rane-
late; calcitonin; parathyroid hormone.
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2.4 | Statistical analyses
Regression analysis with Cox proportional hazards models (SAS 9.4,
PHREG procedure) was used to estimate the fracture rate of current
DPP-4 inhibitor users compared with other NIAD users, excluding
glucagon-like peptide 1 (GLP-1) receptor agonist (RA) users. GLP-1-
RA use was taken into account as a separate exposure group as this
has been associated with a decreased risk of fracture.16 In further
analyses we stratified current DPP-4 inhibitor use by categories of
continuous duration. In all analyses potential confounders were
included if they independently changed the β-coefficient for current
DPP-4 inhibitor exposure by at least 5%, or when consensus about
inclusion existed within the team of researchers, supported by clinical
evidence from the literature. For confounder data with missing values
(BMI, HbA1c, alcohol use and smoking status) a missing indicator var-
iable was added.
2.5 | Sensitivity analyses
As a sensitivity analysis the gap used to determine continuous dura-
tion was changed to 60 and 90 days. In a second sensitivity analyses
we performed a new-user design in which all NIAD users with a
NIAD prescription before the start of the study were excluded from
the analyses. Additionally, we performed a sensitivity analysis in
which all patients with a history of a fracture before the index date
were excluded. A fourth sensitivity analysis was performed in which
we adjusted the main analyses for current use of thiazolidinediones
and current use of sulphonylurea derivatives, as they have both been
associated with fracture risk.17,18
3 | RESULTS
In total 328 254 NIAD users were included, of whom 46 355 were
DPP-4 inhibitor users. The baseline characteristics are shown in
Table 1. The median actual duration of DPP-4 inhibitor use was
1.6 years and the mean duration of follow-up was 6.3 and 5.6 years
for the DPP-4 inhibitor users and the NIAD users, respectively. DPP-
4 inhibitor users were less often women, were slightly younger, and
had a higher HbA1c concentration (8.8% vs 8.0%) and BMI (32.6 vs
31.4 kg/m2) at index date as compared with other NIAD users. His-
tory of retinopathy, use of statins and use of antihypertensives was
higher in DPP-4 inhibitor users at baseline than in other NIAD users.
Table 2 shows that any DPP-4 inhibitor use was associated with
a decreased risk of any fracture (adjusted hazard ratio [HR] 0.93
[95% confidence interval {CI} 0.88-0.94]). Current use of DPP-4 inhi-
bitors was not associated with risk of any fracture (adjusted HR 0.99
[95% CI 0.93-1.06]) as compared with current other NIAD use.
Recent DPP-4 inhibitor use was not associated with risk of fracture
either, whereas past DPP-4 inhibitor use was associated with a
decreased risk of fracture (adjusted HR 0.83 [95% CI 0.75-0.91]). Past
NIAD use was associated with a 60% reduced risk of any fracture
(adjusted HR 0.40 [95% CI 0.38-0.43]). The fully adjusted model
including all potential confounders showed an HR of 0.95 (95% CI
0.89-1.01) with current use of DPP-4 inhibitor and risk of any frac-
ture. Stratification by continuous duration of use resulted in an
increased risk of fracture for patients who continuously used DPP-4
inhibitors for 2.0-2.9 years (adjusted HR 1.23 [95% CI 1.03-1.48]).
Other categories showed no association with continuous duration of
DPP-4 inhibitor use (Table 2).
Any DPP-4 inhibitor use was associated with a decreased risk of
osteoporotic fracture but not with hip fracture (adjusted HR for oste-
oporotic fracture 0.91 [95% CI 0.84-0.98] and for hip fracture 0.92
[95% CI 0.79-1.06]). Current use of DPP-4 inhibitors was not associ-
ated with risk of osteoporotic (adjusted HR 0.96 [95% CI 0.87-1.05])
or hip fracture (adjusted HR 0.96 [95% CI 0.81-1.15]; Table 3). Both
recent and past DPP-4 inhibitor use showed a decreased risk of oste-
oporotic fracture (adjusted HR for recent DPP-4 inhibitor use 0.72
[95% CI 0.52-0.99], past DPP-4 inhibitor use 0.84 [95% CI
0.73–0.96]). Recent and past DPP-4 inhibitor use were not associated
with risk of hip fracture. Past NIAD use was associated with a
reduced risk of major osteoporotic fracture and hip fracture. Current
use of DPP-4 inhibitors stratified by continuous duration of use was
not associated with risk of osteoporotic fracture nor with risk of hip
fracture.
In the first sensitivity analysis we extended the gap between the
expected end date of a prescription and the start of the next pre-
scription to 60 and 90 days, respectively. When the gap was set to
60 days the results for risk of any, osteoporotic or hip fracture did
not substantially change except for continuous duration of DPP-4
inhibitor use of 2.0 to 2.9 years and risk of any fracture, which was
no longer significant (adjusted HR 1.04 [95% CI 0.87-1.24]). When
the gap was set to 90 days, similar results were seen: no materially
altered results for risk of any, osteoporotic or hip fracture except
with 2.0 to 2.9 years of DPP-4 inhibitor use and risk of any frac-
ture, which was no longer significant (adjusted HR 1.04 [95% CI
0.88-1.24]).
In a second sensitivity analysis the study population was
restricted to new users of NIADs. Current DPP-4 inhibitor use strati-
fied by continuous duration of use categories was not associated
with risk of any fracture. Additional adjustment for diabetes duration
did not materially alter the results. In a third sensitivity analysis we
excluded all patients with a history of a fracture. Current use of DPP-
4 inhibitors stratified by continuous duration of use was not associ-
ated with risk of any fracture. Additional adjustments for current use
of thiazolidinediones and sulphonylurea derivatives resulted in a sig-
nificantly decreased risk of any fracture with current DPP-4 inhibitor
use (adjusted HR 0.94 [95% CI 0.88-1.00]).
4 | DISCUSSION
The present study showed that current use of DPP-4 inhibitors was
not associated with risk of any, osteoporotic or hip fracture. After
stratification by continuous duration of use we showed no associa-
tion between the highest continuous duration of DPP-4 inhibitor use
category and any (>4.0-8.5 years of use), osteoporotic (>3.0-8.5 years
of use) or hip (>2.0-8.5 years of use) fracture. Different sensitivity
analyses confirmed the results of no association between current use
of DPP-4 inhibitors and risk of any fracture.
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The present results are in line with the results of 2 recently per-
formed meta-analyses, which included 51 and 62 RCTs, respectively,
comparing DPP-4 inhibitors with placebo or an active compara-
tor.19,20 Both meta-analyses showed no association between use of
DPP-4 inhibitors and risk of fracture. The adverse events fracture
data of a large clinical trial (n = 16 492) comparing saxagliptin, a
DPP-4 inhibitor, with placebo have been analysed in more depth21
and showed a relative risk of 1. The present results are also sup-
ported by the results of an analysis of the fracture data of a cardio-
vascular trial comparing sitagliptin, a DPP-4 inhibitor, with placebo in
patients with T2DM (N = 14 671), which showed no association with
risk of fracture.22
The present results are also consistent with our previous obser-
vational studies comparing current use of DPP-4 inhibitors with use
of other NIADs,8,9 with a meta-analysis of the observational studies23
and with an observational study comparing use of metformin and
DPP-4 inhibitor with non-use.10 The present results are not consist-
ent with a meta-analysis including 28 RCTs comparing DPP-4 inhibi-
tors with placebo or active treatment, which showed a 40% reduced
risk7; however, the 2 updated meta-analyses showed no reduced risk
of fracture with use of DPP-4 inhibitors,19,20 suggesting that the large
reduction in fracture risk found in the first meta-analysis might have
been a consequence of the small number of included trials and the
small number of reported fractures.
It has been shown that DPP-4 inhibitors increase the concentra-
tion of incretin hormones GLP-1 and gastric inhibitory polypeptide
(GIP).5 In vitro research has shown that GIP stimulates osteoblast
TABLE 1 Baseline characteristics of current DPP-4 inhibitor users
and other NIAD users
Characteristic
DPP-4 inhibitor
users (N = 46 355)
Other NIAD users
(N = 281 899)
Mean (s.d.) follow-up
time, years





Women 19 428 (41.9) 114 467 (48.6)
Mean (s.d.) age at index
date, years
59.7 (12.4) 61.5 (16.1)
Age
18-49 years 9883 (21.3) 53 131 (22.6)
50-59 years 12 550 (27.1) 44 660 (19.0)
60-69 years 13 448 (29.0) 56 812 (24.1)
70-79 years 8065 (17.4) 50 561 (21.5)
≥80 years 2409 (5.2) 30 380 (12.9)
Mean (s.d.) BMI at index
date, kg/m2
32.6 (6.7) 31.4 (6.8)
BMI
<20.0 kg/m2 273 (0.6) 3646 (1.5)
20.0-24.9 kg/m2 4044 (8.7) 30 956 (13.1)
25.0-29.9 kg/m2 13 270 (28.6) 71 599 (30.4)
30.0-34.9 kg/m2 14 059 (30.3) 63 347 (26.9)
≥35.0 kg/m2 14 023 (30.3) 57 971 (24.6)
Missing 686 (1.5) 8025 (3.4)
Mean (s.d.) HbA1c 8.8 (1.5) 8 (1.8)
HbA1c
<6% 394 (0.8) 8550 (3.6)
6.0%-6.9% 2807 (6.1) 35 868 (15.2)
7.0%-7.9% 10 418 (22.5) 42 017 (17.8)
8.0%-8.9% 12 217 (26.4) 22 598 (9.6)
≥9.0% 15 720 (33.9) 31 355 (13.3)
Missing 4799 (10.4) 95 156 (40.4)
Smoking status
Never smoker 14 839 (32.0) 77 335 (32.8)
Current smoker 8015 (17.3) 40 256 (17.1)
Ex-smoker 23 334 (50.3) 116 180 (49.3)
Missing 167 (0.4) 1773 (0.8)
Alcohol use
No 14 349 (31.0) 74 826 (31.8)
Yes 30 416 (65.6) 145 609 (61.8)
Missing 1590 (3.4) 15 109 (6.4)
Falls (in 6-12 months
before index date)
477 (1.0) 2427 (1.0)
History of diseases
Fracture 9575 (20.7) 49 438 (21.0)
Hyperthyroidism 535 (1.2) 2315 (1.0)
Hypothyroidism 4180 (9.0) 18 997 (8.1)
COPD 2765 (6.0) 12 559 (5.3)
Congestive heart
failure
1929 (4.2) 9119 (3.9)
Cancer 11 491 (24.8) 51 587 (21.9)
Rheumatoid arthritis 726 (1.6) 3621 (1.5)




users (N = 46 355)
Other NIAD users
(N = 281 899)
Secondary
osteoporosis
3774 (8.1) 19 655 (8.3)
Neuropathy 3090 (6.7) 10 506 (4.5)
Drug use within 6 months prior to index date
Glucocorticoids 9160 (19.8) 40 683 (17.3)
Statins 34 574 (74.6) 118 488 (50.3)
Antiarrhythmics 641 (1.4) 3464 (1.5)
Antidepressants 9688 (20.9) 38 909 (16.5)
Anti-Parkinson’s
drugs
259 (0.6) 1235 (0.5)
Antipsychotics 997 (2.2) 5794 (2.5)
Anxiolytics/hypnotics 3133 (6.8) 16 402 (7.0)
Antihypertensives 32 411 (69.9) 129 584 (55.0)
Bisphosphonates 1032 (2.2) 6399 (2.7)
Raloxifene 14 (0.0) 282 (0.1)
Calcium/vitamin D 2393 (5.2) 10 574 (4.5)
Strontium 16 (0.0) 126 (0.1)
Parathyroid
hormone/calcitonin




178 (0.4) 820 (0.3)
Data are presented as n (%), unless stated otherwise.
Abbreviations: COPD, chronic obstructive pulmonary disease; IQR, inter-
quartile range; n/a, not applicable; s.d., standard deviation.
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differentiation.24 Treatment with GLP-1 has been associated with an
increase in bone density in rodent models with osteopenia.25,26 It
was therefore hypothesized that DPP-4 inhibitors may reduce frac-
ture risk; however, in the present study, we did not show a decreased
risk of fracture with use of DPP-4 inhibitors. One of the explanations
for this might be that DPP-4 inhibitors have still not been used long
enough to establish this reduced risk of fracture; however, a small
group of patients used DPP-4 inhibitors continuously for >4 years, in
our analysis of risk of any fracture. Antihyperglycaemic drugs that
have been associated with an unintended effect on bone, such as
thiazolidinediones, showed this already after 2 years of use.27,28 In
addition, bisphosphonates, used to prevent fractures, have shown a
reduction in fracture risk after 18 months of use.29,30 GIP and GLP-1
have been shown to be reduced in patients with T2DM.31 It might be
that, because of the use of DPP-4 inhibitors, the levels of GIP and
GLP-1 increase to the normal level, but not to the higher levels
required to have an effect on bone metabolism and, in the end, on
fracture risk.
Current use of DPP-4 inhibitors was associated with an increased
risk of any fracture when patients used them continuously for 2.0 to
2.9 years. Longer use was not associated with an increased fracture
risk, which would be expected if DPP-4 inhibitor use increased frac-
ture risk. In addition, in all sensitivity analyses this increased risk
disappeared, suggesting that this increased risk was a chance finding.
Unexpectedly, past NIAD use was associated with a 60% reduced risk
of any fracture, which is hard to explain and should be interpreted
with caution. Past NIAD use includes use in patients who are
switched to insulin; however, this has been associated with an
increased not a decreased risk of fracture.32
The strengths of the present study include its large sample
size as well as the representativeness of the used CPRD data for
the general population of the UK. In addition, we were able to
adjust for many potential important confounders in a time-
dependent manner. We also had data on important lifestyle fac-
tors, such as BMI, and data on HbA1c concentrations. Moreover,
we were able to investigate the association between current use
of DPP-4 inhibitors for >4.0 to 8.5 years and risk of any fracture.
Additionally, it has been shown that the CPRD fracture data has a
high validity.12
The present study also has some limitations. For osteoporotic
and hip fracture we had to combine the highest categories of contin-
uous duration of use into >3.0 to 8.5 years and >2.0 to 8.5 years,
respectively. Another limitation is that, despite the fact that the
follow-up period was extended by almost 3.5 years as compared with
the previous observational studies,8,9 the median duration of actual
DPP-4 inhibitor use only increased by 0.6 years. Future work is
TABLE 2 Use of DPP-4 inhibitors and risk of any fracture stratified by continuous duration of use
Exposure
Number of fractures







Current NIAD use3 excluding
incretins
12 575 14.3 Reference Reference
Past NIAD use4 1923 3.3 0.23 (0.22-0.24)8 0.40 (0.38-0.43)8
Any DPP-4 inhibitor use 1700 10.3 0.88 (0.83-0.92)8 0.93 (0.88-0.94)8
By recency
Past DPP-4 inhibitor use5 479 7.6 0.65 (0.59-0.72)8 0.83 (0.75-0.91)8
Recent DPP-4 inhibitor use6 93 9.9 0.84 (0.68-1.03) 0.83 (0.67-1.02)
Current DPP-4 inhibitor use7 1128 12.2 1.02 (0.96-1.08) 0.99 (0.93-1.06)
By continuous duration of use
No continuous duration of use 275 12.0 1.00 (0.89-1.13) 0.97 (0.86-1.09)
≤0.5 year 311 12.2 1.01 (0.90-1.13) 1.00 (0.89-1.12)
0.6-0.9 year 162 11.6 0.96 (0.82-1.12) 0.93 (0.80-1.09)
1.0-1.9 years 192 12.4 1.02 (0.88-1.18) 1.00 (0.87-1.16)
2.0-2.9 years 117 14.9 1.25 (1.04-1.50)8,9 1.23 (1.03-1.48)8,9
3.0-3.9 years 40 9.9 0.86 (0.63-1.17) 0.84 (0.62-1.15)
4.0-8.5 years 31 11.0 1.02 (0.72-1.45) 0.99 (0.70-1.41)
1 GLP-1-RA use not shown, therefore the total numbers of fractures do not add up to the total number of fractures.
2 Adjusted for: age, gender, BMI, smoking status, HbA1c, use of antipsychotics, glucocorticoids, statins, antidepressants, antihypertensives, anxiolytics/
hypnotics, calcium/vitamin D, anti-osteoporotic drugs (use of bisphosphonates, raloxifene, strontium ranelate or parathyroid hormone/calcitonin), his-
tory of fracture, falls, secondary osteoporosis, retinopathy and neuropathy.
3 Current NIAD use: most recent NIAD prescription within 90 days before start of an interval.
4 Past NIAD use: most recent prescription over 90 days before start of an interval.
5 Past DPP-4 inhibitor use: most recent prescription over 180 days before start of an interval.
6 Recent DPP-4 inhibitor use: most recent prescription within 91 to 180 days before start of an interval.
7 Current DPP-4 inhibitor use: most recent prescription within 90 days before start of an interval.
8 Statistically significant (P < 0.05).
9 Statistically significant difference compared with no continuous duration of use, 0.5 to 1 year of continuous duration of use and 3 to 4 years of continu-
ous duration of use, using Wald test (P < 0.05).
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required to evaluate properly the association between long duration
of DPP-4 inhibitor use and the effects on fracture risk, once the dura-
tion data have had sufficient time to mature. Moreover, although we
were able to adjust for many confounders, residual confounding may
be present.
We showed that current use of DPP-4 inhibitors was not associ-
ated with risk of any, osteoporotic or hip fracture. Moreover, we
showed that, when stratified by continuous duration of use, current
use of DPP-4 inhibitors was not associated with a decreased risk of
any (>4.0-8.5 years of DPP-4 inhibitor use), osteoporotic (>3.0-
8.5 years of DPP-4 inhibitor use) or hip (>2.0-8.5 years of DPP-4
inhibitor use) fracture. These findings may be of value for clinical
decisions regarding treatment of people with T2DM, especially those
at high fracture risk.
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